MYRIAD GENETICS Files 8-K on Financial Results and Condition

TL;DR

**MYGN just filed an 8-K reporting its financial results and condition on February 27, 2024.**

AI Summary

MYRIAD GENETICS, INC. (MYGN) filed an 8-K on February 27, 2024, to report on its results of operations and financial condition. This filing also included financial statements and exhibits, as required by the Securities Exchange Act of 1934. The company, incorporated in Delaware, maintains its principal executive offices in Salt Lake City, Utah.

Why It Matters

This routine filing provides investors with updated financial information, which is essential for evaluating MYRIAD GENETICS' performance and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a standard disclosure of financial information, not an announcement of an event that inherently carries high risk.

Key Players & Entities

• MYRIAD GENETICS, INC. (company) — registrant
• February 27, 2024 (date) — date of report
• Delaware (location) — state of incorporation
• Salt Lake City, Utah (location) — principal executive offices

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar

Filing Documents

• mygn-20240227.htm (8-K) — 37KB
• mygn-xq423earningsreleasex.htm (EX-99.1) — 410KB
• 0000899923-24-000014.txt ( ) — 629KB
• mygn-20240227.xsd (EX-101.SCH) — 2KB
• mygn-20240227_def.xml (EX-101.DEF) — 14KB
• mygn-20240227_lab.xml (EX-101.LAB) — 27KB
• mygn-20240227_pre.xml (EX-101.PRE) — 15KB
• mygn-20240227_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

ITEM 2.02 Results of Operations and Financial Condition. On February 27, 2024, Myriad Genetics, Inc. ("Myriad" or the "Company") announced its financial results for the three months ended December 31, 2023. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K and Exhibit 99.1 contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the company's first quarter and fiscal year 2024 financial guidance, and statements relating to the company's continuing investment in Labs of the Future strategy and technology investments, including EMR integrations, designed to enhance its ability to serve more patients seamlessly and efficiently, the company's plans to continue to accelerate its market share gains and improve reimbursement for its products and services, the company's financial flexibility to continue to invest in the research and development and technology innovations to achieve its Mission and Vision to reach more patients with life-saving precision medicine, the company's plans to introduce a number of new products in the second half of 2024 or early 2025, including Foresight Universal Plus, FirstGene, Precise Tumor (relaunch), Precise Liquid, and Precise MRD for research use by our pharma partners. These "forward-looking statements" are management's present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. These risks include, but are not limited to: the risk that sales and profit margins of the company's existing tests may decline; the risk that the company may not be able to operate its business on a profitable basis; risks related to the company's ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to changes in governmental or private insurers' coverage and reimbursement levels for the company's tests or the company's ability to obtain reimbursement for its new t

01 Financial Statements and Exhibits

ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Earnings release dated February 27, 2024 for the three months ended December 31, 2023 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The exhibit(s) may contain hypertext links to information on our website or other parties' websites. The information on our website and other parties' websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K. In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: February 27, 2024 By: /s/ Scott J. Leffler Scott J. Leffler Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR